MIF and neoplasm: In terms of mechanism, TA-MSCs, TA-MSCs-EVs and MIF reduce the expression of PD-1 in immunosuppressive TME and PD-L1 in tumor cell and immunosuppressive cell, thereby inhibiting anti-tumor immunity and promoting tumor cell immune escape.